التفاصيل البيبلوغرافية
| العنوان: |
Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon‐beta treatment for multiple sclerosis. |
| المؤلفون: |
Mrabet, Sanda, Dahmane, Rihem, Raja, Boukadida, Fradi, Asma, Aicha, Narjess Ben, Sahtout, Wissal, Azzabi, Awatef, Guedri, Yosra, Zellama, Dorsaf, Achour, Abdellatif, Sfar, Imen, Goucha, Rim, Abdessayed, Nihed, Mokni, Moncef |
| المصدر: |
British Journal of Clinical Pharmacology; May2023, Vol. 89 Issue 5, p1682-1685, 4p |
| مصطلحات موضوعية: |
ECULIZUMAB, INTERFERON beta 1b, MULTIPLE sclerosis, HEMOLYTIC anemia, HEMOLYTIC-uremic syndrome, COMPLEMENT activation, KIDNEY failure |
| مستخلص: |
Aims: Interferon‐beta (IFNβ), the most widely prescribed medication for multiple sclerosis, is generally considered safe. Nevertheless, rare serious and/or life‐threatening side effects have been reported such as thrombotic microangiopathy. A few mechanisms have been proposed to explain how interferon causes thrombotic microangiopathy, but immunological studies have been unable to pin this phenomenon down to a single pathophysiologic pathway. The aim of this article was to report a new mechanism explaining Interferon beta related thrombotic microangiopathy. Methods: We report thrombotic microangiopathy in a 28‐year‐old male receiving interferon‐beta treatment for multiple sclerosis. Results: After three years of starting interferon beta therapy, the patient presented with malignant hypertension causing seizures, rapidly progressive renal failure requiring haemodialysis and haemolytic anaemia. Corticosteroid and plasma exchange sessions permitted haemolysis control. Nonetheless, the patient remained hemodialysis‐dependent. Exploration of the complement system found a complement factor I deficiency whose activity normalized at the control carried out after 2 years. Conclusion: IFNβ treatment may cause complement factor I deficit, which can lead to thrombotic microangiopathy and severe renal failure. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Clinical Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder